TABLE 6.
Hemagglutination-inhibitory activity against Wisc/05 virus of sera from guinea pigs immunized with Pan/99-based live attenuated vaccine
| Guinea piga | Vaccine | Route of challengeb | Titer
|
||
|---|---|---|---|---|---|
| Preimmune | Postinfectionc | Postchallenged | |||
| 59 | PBS | Inoculation i.n. | <10 | <10 | 640 |
| 60 | PBS | Inoculation i.n. | <10 | <10 | 320 |
| 61 | PBS | Exposure | <10 | <10 | 80 |
| 62 | PBS | Exposure | <10 | <10 | 160 |
| 63 | Pan/99 HA NA:PR8 NS1-73 | Inoculation i.n. | <10 | 20 | 80 |
| 64 | Pan/99 HA NA:PR8 NS1-73 | Inoculation i.n. | 10 | <10 | 80 |
| 65 | Pan/99 HA NA:PR8 NS1-73 | Inoculation i.n. | <10 | <10 | <10 |
| 66 | Pan/99 HA NA:PR8 NS1-73 | Inoculation i.n. | <10 | 10 | 20 |
| 67 | Pan/99 HA NA:PR8 NS1-73 | Exposure | <10 | <10 | 40 |
| 68 | Pan/99 HA NA:PR8 NS1-73 | Exposure | <10 | <10 | 40 |
| 69 | Pan/99 HA NA:PR8 NS1-73 | Exposure | <10 | <10 | 10 |
| 70 | Pan/99 HA NA:PR8 NS1-73 | Exposure | <10 | <10 | 80 |
a
Treated with live attenuated vaccine, heterologous challenge (see also Fig. 8).
b
i.n., intranasally.
c
Postvaccination blood samples were collected 42 days after the initial vaccination dose was given.
d
Postchallenge blood samples were collected on day 17 after challenge.